Barclays set a CHF 305 target price on Roche (VTX:ROG) in a report published on Thursday, December 21st. The brokerage currently has a buy rating on the healthcare company’s stock.
A number of other equities analysts also recently commented on the company. Goldman Sachs Group set a CHF 335 price objective on Roche and gave the stock a buy rating in a report on Thursday, August 24th. JPMorgan Chase & Co. restated a buy rating on shares of Roche in a report on Monday, September 25th. Jefferies Group set a CHF 290 price objective on Roche and gave the stock a buy rating in a report on Thursday, September 21st. Finally, Credit Suisse Group set a CHF 300 target price on Roche and gave the company a buy rating in a report on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. Roche currently has an average rating of Hold and an average price target of CHF 263.42.
Shares of Roche (ROG) traded up CHF 1.30 during trading hours on Thursday, reaching CHF 245.80. The company’s stock had a trading volume of 1,680,000 shares, compared to its average volume of 1,550,000. Roche has a 12-month low of CHF 226.10 and a 12-month high of CHF 273. The firm has a market cap of $212,060.00 and a price-to-earnings ratio of 21.85.
TRADEMARK VIOLATION NOTICE: “Roche (ROG) Given a CHF 305 Price Target at Barclays” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/14/roche-rog-pt-set-at-chf-305-by-barclays.html.
Roche Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.